Advaxis Revenue and Competitors
Estimated Revenue & Valuation
- Advaxis's estimated annual revenue is currently $15M per year.
- Advaxis's estimated revenue per employee is $267,857
- Advaxis's total funding is $153.3M.
Employee Data
- Advaxis has 56 Employees.
- Advaxis grew their employee count by -5% last year.
Advaxis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO and President | Reveal Email/Phone |
3 | Interim Chief Financial Officer | Reveal Email/Phone |
4 | Executive Director | Reveal Email/Phone |
5 | EVP & CHIEF MEDICAL OFFICER | Reveal Email/Phone |
6 | Associate Director Facilities/Warehouse and Materials Manager | Reveal Email/Phone |
7 | Associate Director Quality Assurance | Reveal Email/Phone |
8 | Manager, IT & Facilities | Reveal Email/Phone |
9 | Senior Manager, Quality (QA/QC) | Reveal Email/Phone |
10 | Chair Scientific Advisory Board | Reveal Email/Phone |
Advaxis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1239.9M | 13625 | 13% | N/A | N/A |
What Is Advaxis?
Advaxis, Inc. is a biotechnology company based upon the concept that in order to treat cancer and other diseases immunologically it is best to use a modified infectious micro-organism to elicit the most profound immune response possible, as this is what the immune system evolved to address. Based upon over a 10 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of simultaneously stimulating every numerous aspects of the immune sys. tem simultaneously; thus coordinating innate, humoral (antibody), and cellular adaptive immune responses in an extremely effective response to existing cancers and other diseases. Unlike other therapeutic approaches, Advaxis’ Listeria technology has been able to constantly demonstrate complete therapeutic responses resulting in complete tumor regression, even in the presence of immune tolerance. The Company is the exclusive licensee of a broadly enabling platform technology for creating cancer vaccines and therapies for infectious diseases and other immune problems based upon genetically modified Listeria.
keywords:Biotechnology
$153.3M
Total Funding
56
Number of Employees
$15M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Advaxis News
Advaxis, Inc. (ADXS) is near the bottom in its sector according to InvestorsObserver. ADXS gets an overall rating of 55.
Advaxis, Inc. (ADXS) stock is lower by -84.29% over the last 12 months. InvestorsObserver's proprietary ranking system, gives ADXS stock a...
MONMOUTH JUNCTION, N.J., April 08, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on...
MedImmune and Advaxis partner on immuno-oncology combination clinical trial 22-07-2014 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing ...
MedImmune and Advaxis partner on immuno-oncology combination clinical trial 22-07-2014 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing ...
Other Companies in Princeton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.3M | 56 | -10% | N/A |
#2 | $3.5M | 56 | -25% | N/A |
#3 | $7.3M | 56 | 75% | N/A |
#4 | $7.3M | 58 | 45% | N/A |
#5 | N/A | 59 | 26% | N/A |